Loading clinical trials...
Loading clinical trials...
A RandomIzed, Double-Blind, Placebo-CoNtrolled, Two-Part Study to Evaluate the Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With SoRbitol Dehydrogenase (SORD) DEficiency
Conditions
Interventions
AT-007
Placebo
Locations
10
United States
University of Colorado
Aurora, Colorado, United States
University of Miami
Coral Gables, Florida, United States
University of Iowa
Iowa City, Iowa, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Hassman Research Institute
Berlin, New Jersey, United States
University of Rochester
Rochester, New York, United States
Start Date
January 1, 2022
Primary Completion Date
October 12, 2024
Completion Date
October 1, 2026
Last Updated
September 15, 2025
Lead Sponsor
Applied Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions